180 likes | 352 Views
Arthritis Foundation Arthritis Ambassador Briefing. Dial In: 1-866-487-9460 Participant Code: 931 709 2991# Materials available for download at http://www.arthritis.org/ambassador_assignment.php. September 11, 2013 3PM Eastern. Agenda.
E N D
Arthritis Foundation Arthritis Ambassador Briefing Dial In: 1-866-487-9460 Participant Code: 931 709 2991# Materials available for download at http://www.arthritis.org/ambassador_assignment.php September 11, 2013 3PM Eastern
Agenda • Welcome & August Recap – Laurie Markle, Manager Grassroots Advocacy • Ambassador Experience– Hanna Gruen (PA-14) • How Limiting Cost Sharing for Specialty Drugs would Impact Insurance Premiums- Maria Spencer, Director Federal Affairs • September Ambassador Assignment– Laurie Markle • Reporting Your Activity– Laurie Markle • Housekeeping– Laurie Markle • Q&A 1
August Recess Recap 33 Congressional Meetings & Town Halls Results pending. Email to follow. 3
Ambassador Experience On the phone: Hanna Gruen, PA-14 Ambassador 4
HR 460 Impact on Premiums The Problem: Health insurance companies are placing vital, life-changing and life-saving medications including biologics on specialty tiers and charging a co-insurance or percentage of the cost of the drug, instead of a copay. This practice is placing a substantial financial burden on patients. Some patients may pay hundreds or thousands of dollars per month for a medication that was traditionally on a fixed co-pay. 5
HR 460 Impact on Premiums The Solution: The Patients’ Access to Treatments Act (H.R. 460): Requires plans to limit cost sharing requirements for specialty drug tiers to the level of cost sharing required for non-preferred brand drug tiers; there can be no more than a 10% difference in total dollar cost sharing for any drugs on a tier. 6
HR 460 Impact on Premiums Arthritis Foundation and 22 other organizations formed the Coalition for Accessible Treatments (CAT) in support of the Patients’ Access to Treatments Act (H.R. 460) CAT commissioned a study to address Congressional concerns about PATA’s impact on premiums. Study Conclusion: Limiting Specialty Drug Coinsurance does not have a large impact on premiums. The bill would increase premium costs by $3 per year, absent any other changes to the average benefit design. 7
HR 460 Impact on Premiums • What are we doing? • CAT hosted a press conference to release study results Sept. 10th • CAT will host a Senate briefing Sept. 19th • Goal: gain additional co-sponsors in the House; Senate bill introduced 8
September Ambassador Assignment We need Senate Health Legislative Assistants at the Briefing on September 19th! PRESS EVENT AMBASSADOR BRIEFING CALLS & EMAILS CALLS & EMALS CALLS & EMAILS SENATE BRIEFING CALLS & EMAILS CALLS & EMALS CALLS & EMAILS CALLS & EMAILS 9
September Ambassador Assignment Accessing the resources you need www.arthritis.org/ambassador_assignment.php 12
Reporting Your Activity POSTIVE RSVPs should be reported to Geoff Steber at gsteber@arthritis.org Report your activity & receive credit at www.arthritis.org/report • Username: Your email address • Password: Last Name 16
Housekeeping Remaining Ambassador Briefings: October 2, 2013 @ 3PM Eastern November 6, 2013 @ 3PM Eastern Ambassador Awards are awarded annually based on activity reported October-October. 2013 Award recipients will be announced at the November 6th briefing. 17